Cargando…

Short Research Communication Anti-Spike Antibody Response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients

INTRODUCTION: There is limited data on the serologic antibody responses after the ChAdOx1 vaccine in patients with hematological malignancies and hematopoietic cell transplantation recipients. There is no data on the safety and efficacy of the Indian COVISHIELD™ vaccine in this population. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chopra, Madhu, Jain, Arihant, Chhabra, Sanjeev, Kaundal, Shaweta, Singh, Charanpreet, Jandial, Aditya, Prakash, Gaurav, Khadwal, Alka, Das, Chandan, Singh, Mini P, Das, Reena, Malhotra, Pankaj, Lad, Deepesh P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891427/ https://www.ncbi.nlm.nih.gov/pubmed/35261492 http://dx.doi.org/10.1007/s12288-022-01528-y

Ejemplares similares

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance
por: Nair, Ashwin, et al.
Publicado: (2023)

Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial)
por: Singh, Charanpreet, et al.
Publicado: (2022)

Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India
por: Khaire, Niranjan S., et al.
Publicado: (2022)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
por: Prakash, Gaurav, et al.
Publicado: (2021)

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022)

Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation
por: Khaire, Niranjan S., et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers
por: Verma, Alka, et al.
Publicado: (2022)

A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients
por: Bhattacharjee, Urmimala, et al.
Publicado: (2023)

Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022)

Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022)

Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
por: Devi, Leimapokpam Sumitra, et al.
Publicado: (2022)

Post Covishield (ChAdOx1 nCoV-19) Vaccination: New Onset Focal Segmental Glomerulosclerosis Resistant to Steroid and Calcineurin Inhibitor
por: Jha, Vijoy Kumar, et al.
Publicado: (2022)

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
por: Jain, Arihant, et al.
Publicado: (2020)

Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022)

Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine
por: Rizvi, Imran, et al.
Publicado: (2022)

Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications
por: Sahoo, Soumya Swaroop, et al.
Publicado: (2022)

Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study
por: Velhal, Gajanan D., et al.
Publicado: (2022)

COVID‐19 vaccine (ChAdOx1 nCoV‐19 Corona virus vaccine (Recombinant) – COVISHIELD related MS relapse
por: Mathew, Thomas, et al.
Publicado: (2021)

Parsonage-Turner Syndrome Following Covishield (AstraZeneca ChAdOx1 nCoV-19) Vaccination: A Case Report
por: Lakkireddy, Maheshwar, et al.
Publicado: (2022)

Chronic Lymphocytic Leukemia: Real-World Data From India
por: Tejaswi, V., et al.
Publicado: (2020)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
por: Natung, Tanie, et al.
Publicado: (2023)

Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study
por: Kamal, Deep, et al.
Publicado: (2021)

Prevalence of Covishield COVID-19 Vaccine (ChAdOx1 nCoV-19) Adverse Effects among Health Care Workers in Sri Lanka
por: Manilgama, S.R., et al.
Publicado: (2022)

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield(TM)) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
por: Murali, Sharan, et al.
Publicado: (2022)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
por: Vaishya, Raju, et al.
Publicado: (2021)

Complications and management of coagulation disorders in leukemia patients
por: Lad, Deepesh, et al.
Publicado: (2017)

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
por: Konu, Yao Rodion, et al.
Publicado: (2021)

Covishield™ (ChAdOx1 nCoV-19) Vaccine-Induced Systemic Drug-Related Intertriginous and Flexural Exanthema in a Young Girl: A Case Report and Literature Review
por: Sandhu, Jaspriya, et al.
Publicado: (2022)

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study
por: Meher, Trupti, et al.
Publicado: (2023)

A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India
por: Kulkarni, Prasad S, et al.
Publicado: (2021)

Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study
por: Subedi, Prativa, et al.
Publicado: (2021)

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center
por: Prasad, Narayan, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_keo4hdpem3h46gkaiar7ciderc